Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




The Days of Glucose Finger Prick Tests May Be Numbered

By LabMedica International staff writers
Posted on 14 Apr 2011
Consistent blood glucose monitoring based on painful finger pricking could soon be a thing of the past, thanks to a novel prototype sensor that will measure the amount of glucose in a tear drop. More...


Researchers at Arizona State University (ASU; Phoenix, USA) and the Mayo Clinic (Rochester, MN, USA) are developing the new sensor, which has already demonstrated proof-of-concept, as the amount of glucose in tears closely correlates with the amount of glucose in the blood. The device incorporates screen-printed sensors integrated with a silicone rubber fluidics system and absorbent polyurethane foam. In laboratory tests, a simulated eye surface was prepared using fluid-saturated poly(2-hydroxyethyl methacrylate) sheets; the disposable prototype was then tested for both reproducibility at 0 µmol/L, 200 µmol/L, and 400 µmol/L glucose and dynamic range of glucose detection from 0 µmol/L to 1000 µmol/L glucose.

Testing of the integrated prototype demonstrated a satisfactory lower limit of detection for measuring glucose concentration in tears, and was reproducible across a physiological sampling range. The next step in the device design process will be initial animal studies to evaluate the current prototype for factors such as eye irritation, ease of use, and correlation with blood glucose. The major challenges now facing the researchers are performing the test quickly, efficiently, with reproducible results, without letting the test sample evaporate, and without stimulating a stress response that causes people to rub their eyes intensely.

"The problem with current self-monitoring blood glucose technologies is not so much the sensor,” said codeveloper bioengineer Jeffrey LaBelle, PhD, of ASU. "It's the painful finger prick that makes people reluctant to perform the test. This new technology might encourage patients to check their blood sugars more often, which could lead to better control of their diabetes by a simple touch to the eye.”

Because of its potential impact on health care, the technology has drawn interest from BioAccel (Phoenix, USA), a nonprofit organization that works to accelerate efforts to bring biomedical technologies to the marketplace. BioAccel will provide assistance using a network of technical and business experts, while the researchers will compile the proper data set to allow for approval of human testing of the device.

"A critical element to commercialization is the validation of technology through proof-of -concept testing,” said Nikki Corday, BioAccel business and development manager. "Positive results will help ensure that the data is available to help the research team clear the technical hurdles to commercialization.”

Related Links:

Arizona State University
Mayo Clinic
BioAccel



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.